These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26972640)

  • 1. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
    Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Radiation Treatment at a High-Volume Center on Outcomes in Intermediate-Risk Prostate Cancer: An Analysis of the National Cancer Database.
    Lim M; Qureshi MM; Boyd G; Hirsch AE
    Urology; 2022 Jul; 165():242-249. PubMed ID: 35182584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.
    Patel SA; Goyal S; Liu Y; Moghanaki D; Patel PR; Hanasoge S; Dhere VR; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck BW
    JAMA Netw Open; 2020 Dec; 3(12):e2025143. PubMed ID: 33301015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
    Bajaj A; Martin B; Bhasin R; Hentz C; Block AM; Harkenrider MM; Solanki AA
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):851-857. PubMed ID: 29485062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes of Whole-Pelvic Versus Prostate-Only Radiation Therapy for High-Risk Prostate Cancer Patients With Use of the National Cancer Data Base.
    Amini A; Jones BL; Yeh N; Rusthoven CG; Armstrong H; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1052-63. PubMed ID: 26581142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.
    Wright JD; Huang Y; Ananth CV; Tergas AI; Duffy C; Deutsch I; Burke WM; Hou JY; Neugut AI; Hershman DL
    Gynecol Oncol; 2015 Dec; 139(3):506-12. PubMed ID: 26177552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.
    Sebastian N; Goyal S; Liu Y; Janopaul-Naylor JR; Patel PR; Dhere VR; Hanasoge S; Shelton JW; Godette KD; Jani AB; Hershatter B; Fischer-Valuck B; Patel SA
    JAMA Netw Open; 2023 Aug; 6(8):e2327637. PubMed ID: 37552479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Facility Volume and Survival in Nasopharyngeal Carcinoma.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Lee NY; Ho AS; Zumsteg ZS
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):408-417. PubMed ID: 29100787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Treatment at High-Volume Facilities and Improved Overall Survival in Soft Tissue Sarcomas.
    Venigalla S; Nead KT; Sebro R; Guttmann DM; Sharma S; Simone CB; Levin WP; Wilson RJ; Weber KL; Shabason JE
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):1004-1015. PubMed ID: 29485042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
    Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
    Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of treating facilities' type and volume in patients with major salivary gland cancer.
    Bollig CA; Zitsch RP
    Laryngoscope; 2019 Oct; 129(10):2321-2327. PubMed ID: 30698823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.